登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>IL-4 >IL4-H4218

Human IL-4 Protein, premium grade

GMP version GMP-L04H26 is now available for seamless transition.

分子别名(Synonym)

IL4,BCGF1,BSF1

表达区间及表达系统(Source)

Human IL-4, premium grade (IL4-H4218) is expressed from human 293 cells (HEK293). It contains AA His 25 - Ser 153 (Accession # P05112-1).

Predicted N-terminus: His 25

It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage.
GMP-L04H26 is the GMP version of this IL4-H4218. These two proteins display indistinguishable performance profiles, thereby ensuring a seamless transition for end users from early preclinical stag to later clinical phases.

Request for sequence

蛋白结构(Molecular Characterization)

IL-4 Structure

This protein carries no "tag".

The protein has a calculated MW of 15.0 kDa. The protein migrates as 19 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 0.01 EU per μg by the LAL method.

宿主蛋白残留(Host Cell Protein)

<0.5 ng/µg of protein tested by ELISA.

宿主核酸残留(Host Cell DNA)

<0.02 ng/μg of protein tested by qPCR.

无菌(Sterility)

Negative

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

>95% as determined by SEC-HPLC.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

IL-4 SDS-PAGE

Human IL-4, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-HPLC

IL-4 SEC-HPLC

The purity of Human IL-4, premium grade (Cat. No. IL4-H4218) was greater than 95% as determined by SEC-HPLC.

 

活性(Bioactivity)-CELL BASE

IL-4 CELL

Human IL-4, premium grade (Cat. No. IL4-H4218) stimulates proliferation of TF-1 human erythroleukemic cell line. The specific activity of Human IL-4, premium grade is > 1.20×10^7 IU/mg, which is calibrated against human IL-4 WHO International Standard (NIBSC code: 88/656) (QC tested).

Protocol

IL-4 BATCH CELL BASE

Activity of three different production batches of Human IL-4 Protein, premium grade (Cat. No. IL4-H4218).

IL-4 CELL

The activity of Human IL-4 Protein, premium grade (Cat. No. IL4-H4218) was higher than other competing products.

 

活性(Bioactivity)-ELISA

IL-4 ELISA

Immobilized Human IL-4, premium grade (Cat. No. IL4-H4218) at 5 μg/mL (100 μL/well) can bind Human IL-4 R alpha, Fc Tag (Cat. No. ILR-H5253) with a linear range of 0.001-0.031 μg/mL (QC tested).

Protocol

IL-4 ELISA

Immobilized Human IL-4, premium grade (Cat. No. IL4-H4218) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-4 R alpha, Fc,Avitag (Cat. No. ILR-H82F4) with a linear range of 0.008-0.125 μg/mL (Routinely tested).

Protocol

 

稳定性(Stability)

IL-4 STABILITY

The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG IL-4.

 
评论(7)
  1. 156XXXXXXX8
  2. 5人赞
  3. 购买该蛋白用于巨噬细胞诱导,开展巨噬细胞相关功能性验证实验,在添加M-CSF和IL-4的情况下,可以诱导PBMC和THP1细胞分化成为具有免疫抑制作用的M2型巨噬细胞。
  4. 2021-8-19
  1. 187XXXXXXX9
  2. 1人赞
  3. 这个我们用来做ELISA的,效果还是比较不错的,梯度很好,主要和我们的抗体匹配度比较高,实验做起来挺轻松的,这个质量还是比较稳定的,发货也快,比较适合科研
  4. >
  5. 2022-11-18
  1. 156XXXXXXX8
  2. 0人赞
  3. 该多效细胞因子IL4主要用于体外细胞诱导协同GMCSF作用,成功诱导获得的细胞性能稳定,目的细胞能较好的组成型表达特异性表面标记物,为后续实验提供有力支撑。
  4. >
  5. 2023-9-6
 
ACRO质量管理体系
 
 

背景(Background)

Interleukin-4, is a cytokine that induces differentiation of naive helper T cells (Th0 cells to Th2 cells). In the presence of IL-4 and IL-13, cytokines that are produced in a Th-2 type response, particularly during allergy and parasitic infections, macrophages become differentially activated, And this cytokine is a ligand for interleukin 4 receptor. The interleukin 4 receptor also binds to IL13, which may contribute to many overlapping functions of this cytokine and IL13. STAT6, a signal transducer and activator of transcription, has been shown to play a central role in mediating the immune regulatory signal of this cytokine. Recently, researcher found that the cytokine IL-4 plays a key role in development of innate CD8+ T cells in the thymus of several gene-deficient mouse strains, including Itk, KLF2, CBP and Id3, without previous exposure to antigen.

文献引用(Citations)

 

前沿进展

Extracellular Vesicles (EVs) Derived from Mesenchymal Stem Cells (MSCs) as Adjuvants in the Treatment of Chronic Kidney Disease (CKD)
Noda, Francini, Teles et al
Cells (2025) 14 (6)
Abstract: Chronic kidney disease (CKD) is considered an important health issue worldwide. The renin-angiotensin-aldosterone system (RAAS) blockade through the administration of angiotensin II receptor blockers, such as Losartan (LOS), has been considered the best strategy for CKD treatment for decades. However, this approach promotes only partial detention of CKD progression and cannot reverse renal damage. The aim of the present study was to investigate whether the therapeutic administration of extracellular vesicles (EVs) derived from adipose stem cells (ASCs), associated to LOS treatment, would promote additional renoprotection in rats underwent the 5/6 renal ablation CKD model. ASC-derived EV were administered locally, in the renal subcapsular area, 15 days after CKD induction, when LOS therapy also began. Animals were followed for additional 15 days and our results demonstrated that subcapsular injection of ASC-derived EV associated with LOS significantly reduced glomerulosclerosis, renal interstitial infiltration by myofibroblasts, and macrophages in the 5/6 CKD model. Additionally, LOS + EV abrogated systemic hypertension, proteinuria, and albuminuria, and stimulated local gene overexpression of the endogenous anti-inflammatory Il-4. Although more studies are still required to establish the best EV dose and administration route, these findings point to therapy with ASC-derived EV as a potential adjuvant in CKD treatment.
Dupilumab, a Potential Novel Treatment for Hailey-Hailey Disease
Popa, Giurcaneanu, Zaharia et al
Clin Pract (2025) 15 (3)
Abstract: Background/Objectives: Hailey-Hailey disease (HHD) is an uncommon genodermatosis with autosomal dominant inheritance caused by loss-of-function mutations in the ATP2C1 gene, which lead to disruption in keratinocyte adhesion and intraepidermal acantholysis. The chronic nature of the disease, its frequent recurrences and the lack of specific treatment pose real challenges in the long-term management of these patients. Recent studies have evaluated the effect of dupilumab, a human monoclonal antibody that blocks interleukin-4 and -13 receptor in refractory HHD, with very promising results. The aim of this study was to review the published data on the use of dupilumab for the treatment of HHD, to present our own experience in the field, and to discuss the mechanisms underlying dupilumab's beneficial effects in HHD and the future treatment perspectives. Methods: A search of the medical literature on the use of dupilumab in the treatment of HHD was conducted. The terms "Hailey-Hailey disease", "benign familial pemphigus", "benign chronic pemphigus", and "dupilumab" were searched across multiple databases (Medline, Chrocane Library, EMBASE) from inception until 30 September 2024. Results: To date, six manuscripts describing 11 refractory HHD cases treated with dupilumab have been published. All the patients experienced significant clinical improvement. The authors reported sustained disease quiescence in seven patients (64%), monitored for 5 to 24 months. None of the patients experienced adverse effects related to dupilumab. To the existing evidence, we add a new case of recalcitrant HHD successfully treated with dupilumab. Conclusions: Mounting evidence indicates dupilumab as a safe and efficient therapeutic alternative in patients with severe, refractory HHD. However, the long-term efficacy of dupilumab and the optimal therapeutic regimen for HHD are yet to be determined.
Nitric Oxide Donor Metallodrug: Single-Inhaler Proposal for Rescue in Acute Allergic Asthma Crises
Costa, Waller, Ramos et al
Biology (Basel) (2025) 14 (3)
Abstract: Allergic asthma is characterized by chronic airway inflammation and recurrent bronchial hyperreactivity, highlighting the need for rapid therapeutic interventions during acute crises. This study aimed to assess the potential of a single-dose administration of the ruthenium nitrosyl complex cis-[Ru(bpy)2(2-MIM)(NO)](PG6)3 (named as FOR811A) as a fast-acting treatment in a murine model of allergic asthma. Female Swiss mice were sensitized with ovalbumin for the induction of asthma and subjected to inhalation challenges. The experimental groups included controls and ovalbumin-sensitized mice receiving FOR811A (0.75 mg/kg) or saline (NaCl 0.9%), both by gavage. Lung tissues were collected for analyses of oxidative damage (nitrite/nitrate and GSH), inflammatory markers (myeloperoxidase, IL-1β, and IL-4), and histological assessment. The results showed that, while FOR811A did not significantly reduce oxidative damage or overall inflammation, it effectively decreased IL-4 levels, indicating a modulation of the Th2 immune response without affecting IL-1β levels (Th1 response). These findings suggest that a single-dose administration of FOR811A may provide a rapid therapeutic effect in allergic asthma crises by promoting smooth muscle relaxation and modulating immune responses. Further research is warranted to explore its clinical utility as a fast-acting rescue medication for acute asthma management.
CRISPR/Cas9-mediated deletion of a kinetoplast-associated gene attenuates virulence in Leishmania major parasites
Darzi, Khamesipour, Tasbihi et al
Med Microbiol Immunol (2025) 214 (1), 16
Abstract: We employed a CRISPR/Cas9 technique in Leishmania major to evaluate its efficiency in editing a kDNA-associated gene, the universal minicircle sequence binding protein (UMSBP), which is involved in mitochondrial respiration and kinetoplast division. Using this toolkit, we generated UMSBP mNG-tagged and single knockout L. major (LmUMSBP+/-) parasites, which were confirmed by PCR, confocal microscopy and Western blot analyses. The growth rate of promastigotes in culture and their infectivity in macrophages were analysed in vitro. Mice were immunized with the LmUMSBP+/- mutant strain, and lesion size and parasite burden were measured upon challenge with wild-type (WT) L. major. Cytokines were quantified in supernatants of lymph node cell cultures. The results suggested successful expression and localization of the UMSBP mNG-tagged protein within the kinetoplast in both promastigote and intracellular amastigote forms, confirming the consistency of fluorescence tagging throughout various stages of the Leishmania life cycle. Attenuated LmUMSBP+/- parasites showed significantly reduced growth in culture (P < 0.05), increased apoptosis (P < 0.05) and downregulation of tryparedoxin peroxidase (TXNPx) and trypanothione synthetase (TryS) gene expression compared to WT L. major. LmUMSBP+/- mutant strains did not cause lesions in a susceptible BALB/c mouse model. Furthermore, immunization with LmUMSBP+/- parasites elicited a Th1 immune response, characterized by significantly higher IFN-γ and lower IL-4 production in cell culture (P < 0.001), which was associated with partial protection against WT L. major challenge, as evidenced by reduced parasite burden and lesion development in BALB/c mice. In this study, we successfully validated a practical CRISPR/Cas9 toolkit in L. major, targeting the kinetoplast-associated gene UMSBP. Our findings suggest that the UMSBP single-allele knockout mutant holds promise as a valuable tool for studying the role of the kinetoplast in Leishmania biology and as a potential candidate for further investigation as a live-attenuated vaccine against Leishmania infection.© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Showing 1-4 of 63704 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
IL-4靶点信息
英文全称:Interleukin-4
中文全称:白细胞介素-4
种类:Homo sapiens
上市药物数量:1详情
临床药物数量:9详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定